Moleculin Biotech, Inc. — fact timeline

Moleculin Biotech, Inc. reported financial results for first quarter ended March 31, 2026.

“On May 15, 2026, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026 and recent operational highlights.”

Moleculin Biotech, Inc. reported financial results for the year ended December 31, 2025.

“Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026”

Moleculin Biotech, Inc. issued up to 6,367,956 shares of Company common stock of warrant to holders of certain existing warrants.

“The Company issued the Inducement Warrants pursuant to the exemption from the registration requirements of the Securities Act available under Section 4(a)(2).”

Moleculin Biotech, Inc. entered into Inducement Letter with holders of certain existing warrants valued at approximately $8.3 million (effective 2026-02-19).

“On February 19, 2026, Moleculin Biotech, Inc. (the “Company”) entered into warrant exercise inducement offer letters (each, an “Inducement Letter”) with holders of certain existing warrants (the “Holders”) to purchase up to 2,122,652 shares of Company common stock with an exercise price of $3.90 per share (the “Existing Warrants”).”

Moleculin Biotech, Inc. amended Warrant Amendment with holders of the Company’s Series E warrants, Series F warrants, and Series G warrants valued at $3.90 per share (effective 2025-12-21).

“On December 21, 2025, Moleculin Biotech, Inc. (the “Company”) entered into separate warrant amendment agreements (collectively, the “Warrant Amendment”) with the holders of the Company’s Series E warrants (the “Series E warrants”), Series F warrants (the “Series F warrants”), and Series G warrants (the “Series G warrants,” and collectively with the Series E warrants and Series F warrants, the “Warrants”).”

Moleculin Biotech, Inc. entered into Inducement Letters with holders of existing Series C, Series D, and Series F warrants valued at up to approximately $6.8 million (effective 2025-12-09).

“On December 9, 2025, Moleculin Biotech, Inc. (the “Company”) entered into warrant exercise inducement offer letters (the “Inducement Letters”) with: (i) the holder of existing Series C warrants and Series D warrants to purchase an aggregate of up to 727,969 shares of Company common stock”

Moleculin Biotech, Inc. issued 250% of the number of shares of Company common stock underlying the exercised Existing Warrants, comprised of new Series G warrants to purchase up to 2,610,823 of warrant to holders of existing Series C warrants, Series D warrants and Series F warrants for aggregate gross proceeds of up to approximately $6.8 million from the exercise of the Existing Warrants.

“registration statements on Form S-1 (File No. 333-286276) and Form S-3 (File No. 333-290418). The Company anticipates receiving aggregate gross proceeds of up to approximately $6.8 million from the exercise of the Existing Warrants before deducting fees and other expenses payable by it. Each Inducement Warrant has an exercise price of $6.63 per share, will be”

Moleculin Biotech, Inc.: Approved amendment to certificate of incorporation to effect a 1-for-25 reverse stock split of common stock, effective December 1, 2025 (effective 2025-12-01).

“At the Moleculin Biotech, Inc. (the “Company”) annual meeting of stockholders completed on August 18, 2025, the stockholders of the Company approved an amendment to the Company’s amended and restated certificate of incorporation (the “Amendment”) to effect the reverse stock split at a ratio in the range of 1-for-2 to 1-for-30, with such ratio to be determined in the discretion of the Company’s board of directors and with such reverse stock split to be effected at such time and date, if at all, as determined by the Company’s board of directors in its sole discretion prior to the one-year anniversary of the annual meeting.”

Moleculin Biotech, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

“November 20, 2025, the Company received a delist determination letter from the Staff (the “Nasdaq Notice”) advising the Company that the Staff had determined that the Company had not regained compliance with the Listing Rule. Accordingly, the Staff indicated that unless the Company requests a hearing panel (a “Panel”) appeal of the delist determination by November 28, 2025, its securities would be delisted on December 2, 2025. The Company intends to appeal Nasdaq’s determination to a Panel pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series to stay any suspension pendin”

Moleculin Biotech, Inc.: Stockholders approved a Certificate of Amendment to increase authorized common stock from 100,000,000 to 500,000,000 shares, effective upon filing with the Delaware Secretary of State on August 21, 2025 (effective 2025-08-21).

“As previously disclosed, at the Moleculin Biotech, Inc. (the “Company”) annual meeting of stockholders held on August 18, 2025, the Company’s stockholders approved, among other matters, a proposal to approve a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate Amendment”) which would amend the Company’s existing certificate of incorporation, as amended, to increase the number of authorized shares of the Company’s common stock from 100,000,000 shares to 500,000,000 shares.”

Moleculin Biotech, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“June 27, 2025, Moleculin Biotech, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The deficiency letter does not result in the immediate delisting of the Company’s common stock from the Nasdaq Capital Market. In”

Moleculin Biotech, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“May 23, 2025, Moleculin Biotech, Inc. (the “Company”) received a letter (the “Letter”) from the staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), which notified the Company that it does not presently comply with Nasdaq’s Listing Rule 5550(b)(1) (the “Listing Rule”), which requires that the Company maintain a minimum of $2.5 million in stockholders’ equity, and that the Company also does not meet the alternatives of market value of listed securities or net income from continuing operations set forth in the Listing Rule. The Letter does not h”

Moleculin Biotech, Inc. reported financial results for the quarter ended March 31, 2024.

“On May 13, 2024, Moleculin Biotech, Inc. issued an updated press release announcing its financial results for the quarter ended March 31, 2024 and recent operational highlights.”

Moleculin Biotech, Inc. reported financial results for the quarter ended March 31, 2024.

“On May 13, 2024, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024 and recent operational highlights.”

Moleculin Biotech, Inc. reported the fiscal year ended December 31, 2023 results: net income $29.8 million.

“Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today reported its financial results for the fiscal year ended December 31, 2023.”

Moleculin Biotech, Inc.: Reverse stock split of common stock at 1:15 ratio approved by stockholders and board, effective March 21, 2024 (effective 2024-03-21).

“The Amendment was filed with the Secretary of State of the State of Delaware and the Reverse Stock Split will become effective in accordance with the terms of the Amendment at 11:59 p.m. Eastern Time on March 21, 2024”

Moleculin Biotech, Inc. shareholders approved Approval of issuance of up to 14,089,672 shares of common stock upon exercise of certain warrants as contemplated by Nasdaq Listing Rules 5635(d). at the 2024-02-14 meeting.

“Proposal 1. The NASDAQ Proposal - The Company's stockholders approved the issuance of up to 14,089,672 shares of common stock upon the exercise of certain warrants issued in a private placement that closed on December 26, 2023, as contemplated by Nasdaq Listing Rules 5635(d), as described in more detail in the Proxy Statement, by the following vote: Votes For Votes Against Abstain 5,627,617 2,945,357 4,784,514”

Moleculin Biotech, Inc.: The Board adopted the Fourth Amended and Restated Bylaws, including a clarification that matters presented to stockholders (other than director elections) shall be decided by the affirmative vote of a majority of votes cast (excluding abstentions and broker nonvotes) (effective 2023-12-20).

“On December 20, 2023, the Board of Directors of the Company adopted the Fourth Amended and Restated Bylaws of Moleculin Biotech, Inc. (as amended and restated, the “Bylaws”), effective on such date.”

Moleculin Biotech, Inc. reported financial results for the quarter ended September 30, 2023.

“On November 13, 2023, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023”

Moleculin Biotech, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“November 2, 2023, the Company received an extension of the 180 calendar days from Nasdaq to regain compliance with the Bid Price Requirement, following the expiration of the initial 180 calendar days period to regain compliance. According to the notification from Nasdaq, the determination was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of the Bid Price Requirement, and the Company’s written notice of its intention to cure the defi”

Moleculin Biotech, Inc. shareholders approved Approve an Adjournment - The Company's stockholders approved an adjournment, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Reverse Split Proposal at the 2023-10-03 meeting.

“Proposal 2. Approve an Adjournment - The Company's stockholders approved an adjournment, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Reverse Split Proposal (the “Adjournment Proposal”), by the following vote: Votes For Votes Against Abstain 10,036,330 6,686,830 101,528”

Moleculin Biotech, Inc. shareholders approved To Effect a Reverse Stock Split of the Outstanding Shares - The Company's stockholders approved an amendment to the Company’s amended and restated certificate of incorporation to grant the Board of Directors authority to effect a reverse stock split of the outstanding shares of the Company’s common at the 2023-10-03 meeting.

“Proposal 1. To Effect a Reverse Stock Split of the Outstanding Shares - The Company's stockholders approved an amendment to the Company’s amended and restated certificate of incorporation to grant the Board of Directors authority to effect a reverse stock split of the outstanding shares of the Company’s common stock, at a reverse stock split ratio of between 1-for-5 and 1-for-20 as determined by the Board in its sole discretion, prior to the one-year anniversary of this Special Meeting (the “Reverse Split Proposal”), by the following vote: Votes For Votes Against Abstain 9,796,443 6,858,043 170,202”

Moleculin Biotech, Inc.: Board adopted Third Amended and Restated Bylaws effective August 18, 2023, with multiple changes including reduced stockholder meeting quorum from majority to one-third of voting power (effective 2023-08-18).

“On August 18, 2023, the Board of Directors of Moleculin Biotech, Inc. (the “Company”) adopted the Third Amended and Restated Bylaws of Moleculin Biotech, Inc. (as amended and restated, the “Bylaws”), effective on such date.”

Moleculin Biotech, Inc. reported financial results for the quarter ended June 30, 2023.

“On August 11, 2023, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023 and recent operational highlights.”

Moleculin Biotech, Inc. shareholders rejected Reverse stock split proposal (to approve an amendment to the certificate of incorporation to grant the Board authority to effect a reverse stock split) at the 2023-06-15 meeting.

“stockholders did not approve the Reverse Split Proposal.”

Moleculin Biotech, Inc. shareholders approved Authorize the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting or adjournment or postponement thereof to approve Proposal 5 or Proposal 6 at the 2023-05-25 meeting.

“The authorization to allow for the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting or adjournment or postponement thereof to approve Proposal 5 or Proposal 6 was approved. The votes on the matter were: Votes For Votes Against Abstain 14,006,348 4,841,582 256,502”

Moleculin Biotech, Inc. shareholders rejected Approve an Amendment to the Company's Amended and Restated Certificate of Incorporation to Eliminate Supermajority Voting Requirements to Amend the Amended and Restated Certificate of Incorporation at the 2023-05-25 meeting.

“An amendment to the Company’s Amended and Restated Certificate of Incorporation to eliminate supermajority voting requirements was not approved. Pursuant to the Company’s Amended and Restated Certificate of Incorporation, the affirmative vote of two-thirds of the Company's outstanding shares of common stock is required. The votes on the matter were: Votes For Votes Against Abstain Broker Non-Votes 9,330,880 3,104,649 177,233 6,491,670”

Moleculin Biotech, Inc. shareholders rejected Approve an Amendment to the Company's Amended and Restated Certificate of Incorporation to Increase the Total Authorized Shares from 100,000,000 to 200,000,000 Shares at the 2023-05-25 meeting.

“The Company's stockholders did not approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the total authorized shares, by the following vote: Votes For Votes Against Abstain 11,401,509 7,557,128 145,795”

Moleculin Biotech, Inc. shareholders approved Non-binding, Advisory Resolution to Approve Executive Compensation at the 2023-05-25 meeting.

“The Company's stockholders approved a non-binding, advisory resolution to approve executive compensation, by the following vote: Votes For Votes Against Abstain Broker Non-Votes 8,610,921 3,794,018 207,823 6,491,670”

Moleculin Biotech, Inc. shareholders approved Approve an Increase in the Number of Shares of Common Stock Authorized for Issuance under the 2015 Stock Plan at the 2023-05-25 meeting.

“The Company's stockholders approved an increase in the number of shares of common stock authorized for issuance under the 2015 Plan, by the following vote: Votes For Votes Against Abstain Broker Non-Votes 8,446,330 4,019,327 147,105 6,491,670”

Moleculin Biotech, Inc. shareholders approved Ratify Grant Thornton LLP as Independent Registered Public Accountant at the 2023-05-25 meeting.

“The Company's stockholders ratified the appointment of Grant Thornton, LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023, by the following vote: Votes For Votes Against Abstain 17,267,183 1,660,928 176,321”

Moleculin Biotech, Inc. shareholders approved Election of Directors at the 2023-05-25 meeting.

“The Company's stockholders elected Walter V. Klemp, Robert E. George, Michael D. Cannon, John Climaco, Elizabeth A. Cermak, and Joy Yan to serve until the next Annual Meeting of Stockholders, or until such person's successor is qualified and elected. Director Name Votes For Votes Withheld Broker Non-Votes Walter V. Klemp 10,311,822 2,300,940 6,491,670 Robert E. George 10,358,501 2,254,261 6,491,670 Michael D. Cannon 10,381,531 2,231,231 6,491,670 John Climaco 10,383,776 2,228,986 6,491,670 Elizabeth A. Cermak 10,414,972 2,197,790 6,491,670 Joy Yan 10,416,886 2,195,876 6,491,670”

Moleculin Biotech, Inc. reported financial results for the quarter ended March 31, 2023.

“Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023 and recent operational highlights.”

Moleculin Biotech, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(H)).

“May 5, 2023, Moleculin Biotech, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The deficiency letter does not result in the immediate delisting of the Company’s common stock from the Nasdaq Capital Market. In ac”

Moleculin Biotech, Inc. reported the fiscal year ended December 31, 2022 results: net income $29.0 million.

“The net loss for the year ended December 31, 2022 was $29.0 million, which included non-cash gains of $1.3 million on warrants in 2022 as compared to $6.7 million in the prior year and approximately $2.3 million of stock-based compensation expense in 2022 as compared to $2.4 million in 2021.”

Moleculin Biotech, Inc. terminated At Market Issuance Sales Agreement with Oppenheimer & Co. Inc. valued at up to $50,000,000 (effective 2023-02-03).

“On February 3, 2023, Moleculin Biotech, Inc. (“Company”) delivered written notice to Oppenheimer & Co. Inc. (the “Agent”) that it was terminating its At Market Issuance Sales Agreement, dated June 25, 2021 (the “ATM Agreement”), pursuant to Section 13(b) of the ATM Agreement, effective on February 13, 2023.”

Moleculin Biotech, Inc. reported financial results for the quarter ended September 30, 2022.

“Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported its financial results for the quarter ended September 30, 2022 and provided a pipeline update.”

Joy Yan was appointed as Independent Director at Moleculin Biotech, Inc..

“On March 1, 2022, the Board of Directors of Moleculin Biotech, Inc. (the “Company”) appointed Joy Yan as an independent member of the Company’s Board of Directors, effective on such date.”